University of Maryland Baltimore
Welcome,         Profile    Billing    Logout  
 77 Trials 
203 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lee, Seung Sei
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
NCT05936658: [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer

Recruiting
3
89
RoW
[F-18]Florastamin
FutureChem
High Risk Prostate Carcinoma
12/24
12/24
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
NCT03547791: Effects of ACS in Twin With LPB: Study Protocol for a RCT

Completed
2/3
848
RoW
Betamethason Sodium Phosphate, ACS, Normal saline, NS
Seoul National University Hospital
Twin Pregnancy, Antepartum Condition or Complication
12/23
07/24
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
NCT06249854: Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer

Recruiting
2
70
RoW
Bojungikki-tang(BJIKT), Buzhong Yiqi Decoction, Hochu-ekki-to, Pembrolizumab
Korea Institute of Oriental Medicine
Non-small Cell Lung Cancer
12/25
12/25
NCT06311227: Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Recruiting
2
20
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant
05/27
05/27
PLATINUM, NCT05338619: A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy

Recruiting
2
77
RoW
Lazertinib, LECLAZA
Sung Yong Lee, Yuhan Corporation
Non-small Cell Lung Cancer Stage III, EGFR Positive Non-small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer
03/26
03/26
NCT05506007: A Clinical Trial to Compare the Safety, Tolerability, and PK Properties of DA-5216 and DA-5216-R and to Evaluate the Food Effect on DA-5216.

Recruiting
1
88
RoW
DA-5216, DA-5216-R
Dong-A ST Co., Ltd.
Healthy
10/22
10/22
NCT05992428: Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults

Completed
1
37
RoW
DA-8010 5mg, Paroxetine 20mg, Mirabegron 50mg
Dong-A ST Co., Ltd.
Healthy
11/23
12/23
NCT05321147: Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2

Completed
1
20
US, RoW
lacutamab, IPH4102
Innate Pharma
Peripheral T Cell Lymphoma
11/23
02/24
NCT05703282: A Study to Assess the Safety and Pharmacokinetics of AD-104-A

Completed
1
32
RoW
AD-104-A
Addpharma Inc.
Hyperlipidemias
04/24
04/24
NCT05991401: Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults

Completed
1
18
RoW
DA-8010 5mg, Clarithromycin 500mg, Rifampicin 600mg
Dong-A ST Co., Ltd.
Healthy
11/23
11/23
NCT06164834: Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects

Not yet recruiting
1
48
RoW
Clopidogrel 75 mg, Plavix, Tegoprazan 25 mg, K-CAB, Esomeprazole 20mg, Nexium
HK inno.N Corporation
Healthy
11/24
11/24
NCT06391827: A Study to Evaluate Safety, Tolerability, and PK of DA-7503 in Healthy Adult and Elderly Participants

Not yet recruiting
1
72
RoW
DA-7503 Single dose, DA-7503 Multiple dose, Placebo Single dose, Placebo Multiple dose
Dong-A ST Co., Ltd.
Healthy
05/25
05/25
NCT06736912: This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of IN-114199 in Healthy Participants

Not yet recruiting
1
80
RoW
IN-114199 2.5mg or placebo, IN-114199 10mg or placebo, IN-114199 20mg or placebo, IN-114199 40mg or placebo, IN-114199 5mg or placebo
HK inno.N Corporation
Chronic Idiopathic Constipation
08/25
11/25
NCT05365659: IKS03 in Patients with Advanced B Cell Non-Hodgkin Lymphomas

Recruiting
1
140
Europe, Canada, US, RoW
IKS03
Iksuda Therapeutics Ltd.
B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, B-cell Lymphoma
09/25
09/27
C1763102, NCT05602363: AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Recruiting
1
120
US
Docirbrutinib, AS-1763
Carna Biosciences, Inc.
B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
09/27
09/27
NCT06281054: Acute Myocardial Infarction in Cancer Patients

Active, not recruiting
N/A
4500000
RoW
Revascularization
Samsung Medical Center, Chonnam National University
Acute Myocardial Infarction, Cancer
12/21
12/24
AI-CARPET, NCT06397820: Relation Between AI-QCA and Cardiac PET

Recruiting
N/A
450
RoW
Percutaneous coronary intervention (PCI)
Chonnam National University Hospital
Coronary Artery Disease, Coronary Artery Stenosis
07/24
12/26
NCT04583098: The Effect of Fecal Microbiota Transplantation on the Decolonization of Multidrug-resistant Organisms

Recruiting
N/A
100
RoW
fecal microbiota transplantation
Chuncheon Sacred Heart Hospital
Carbapenem-Resistant Enterobacteriaceae Infection, Vancomycin-Resistant Enterococcal Infection
08/23
08/24
NCT05148052: Effect of Upper Extremity Rehabilitation Using Immersive Virtual Reality in Chronic Stroke Patients.

Recruiting
N/A
36
RoW
Virtual reality exergames, Conventional occupational therapy
Seoul National University Hospital, Asan Medical Center, National Traffic Injury Rehabilitation Hospital, Korea Workers' Compensation and Welfare Service Incheon Hospital
Stroke
08/25
10/25
FRAME-AMI3, NCT06227754: OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts

Recruiting
N/A
1500
RoW
Angiography-guided PCI group, Optical coherence tomography-guided PCI group
Chonnam National University Hospital, Samsung Medical Center
ST Elevation Myocardial Infarction, Myocardial Infarction
12/28
12/29
NCT05493904: PREcise Percutaneous Coronary Intervention for Stent OptimizatION in Treatment of COMPLEX Lesion (PRECISION-COMPLEX)

Recruiting
N/A
320
RoW
OCT-guided PCI, Angiography-guided PCI, Drug-eluting stent
Chonnam National University Hospital, Abbott Medical Devices
Coronary Artery Disease, Angina Pectoris
08/24
12/26
NCT05124249: Imaging and Physiologic Evaluation of Coronary Artery Disease

Recruiting
N/A
2000
RoW
Intravascular imaging (IVUS or OCT) or Invasive physiologic assessment, PCI
Chonnam National University Hospital
Ischemic Heart Disease, Atherosclerosis
12/24
12/27
MANTRA, NCT05002543: CORCYM Mitral, Aortic aNd Tricuspid Post-maRket Study in a reAl-world Setting

Recruiting
N/A
2150
Europe, Canada, US, RoW
Corcym S.r.l
Cardiac Valve Disease
08/25
12/35
NCT06001333: Efficacy and Safety of FMT for the Decolonization of MDROs in the Intestinal Tract

Recruiting
N/A
240
RoW
fecal microbiota transplantation
Chuncheon Sacred Heart Hospital, Severance Hospital, National Institute of Health, Korea
Carbapenem-Resistant Enterobacteriaceae, Vancomycin (Glycopeptide) Resistant Enterococcus (VRE)
12/25
12/26
CMD-MINOCA, NCT05272618: Coronary Microvascular Dysfunction Assessments in Myocardial Infarction With Non-Obstructive Coronary Arteries

Recruiting
N/A
150
RoW
Intravascular imaging (OCT), Invasive physiologic assessment (FFR, CFR, IMR), or Non-invasive physiologic assessment (N-13 ammonia PET)
Chonnam National University Hospital, Korean Cardiac Research Foundation, Abbott
Myocardial Infarction, Coronary Microvascular Dysfunction, Vasospasm, Coronary
12/26
12/27
ASSIST, NCT05529459: Anatomic Versus Physiologic Guidance for Complete Revascularization With DES Eluting in Patients With CAD

Recruiting
N/A
2400
RoW
Percutaneous Coronary Intervention
Seung-Whan Lee, M.D., Ph.D., Biotronik Korea Co., Ltd
Coronary Disease
12/26
07/30
NCT05369182: Multicenter Registry of Coronary Flow-Derived Indexes for Coronary Microvascular Disease (Multicenter FLOW-CMD Registry)

Active, not recruiting
N/A
1000
RoW
Invasive physiologic assessment, Intravascular imaging
Samsung Medical Center, Chonnam National University Hospital, Chosun University Hospital, Seoul National University Bundang Hospital, Seoul St. Mary's Hospital
Coronary Microvascular Disease, Coronary Artery Disease, Ischemic Heart Disease
11/26
12/27
DCB-HBR, NCT05221931: Drug-Coated Balloon in Patients With High Bleeding Risk

Recruiting
N/A
1350
RoW
Percutaneous coronary intervention
Samsung Medical Center, Seoul St. Mary's Hospital, Seoul National University Bundang Hospital, Korea University Ansan Hospital, Chonnam National University Hospital, Chung-Ang University Gwangmyeong Hospital, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gyeongsang National University Hospital, Uijeongbu St. Mary Hospital, Keimyung University Dongsan Medical Center, Inha University Hospital, Chungbuk National University, Wonju Severance Christian Hospital, SMG-SNU Boramae Medical Center, Kangbuk Samsung Hospital, Sungkyunkwan University, Ewha Womans University, Korea University Guro Hospital
Coronary Artery Disease
07/27
12/28
FRAME-AMI2, NCT05812963: IVUS Versus FFR for Non-infarct Related Artery Lesions in Patients With Multivessel Disease and Acute MI

Recruiting
N/A
1400
RoW
IVUS-guided PCI group, FFR-guided PCI group
Samsung Medical Center, Chonnam National University
ST Elevation Myocardial Infarction, Non-ST Elevation Myocardial Infarction
12/28
12/29
Fasano, Alessio
NCT05636293: Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission

Recruiting
2
30
US
Ritlecitinib, Placebo, Gluten
Massachusetts General Hospital, Pfizer
Celiac Disease
08/25
08/25
CDGEMM, NCT02061306: Celiac Disease Genomic Environmental Microbiome and Metabolomic Study

Recruiting
N/A
500
Europe, US
Massachusetts General Hospital, University of Roma La Sapienza, Università Politecnica delle Marche
Celiac Disease
12/24
12/24
GEMMA, NCT04271774: Genome Environment Microbiome and Metabolome in Autism Study

Recruiting
N/A
600
Europe, US
Massachusetts General Hospital, Azienda Sanitaria Locale Salerno, National University of Ireland, Galway, Ireland
Autism Spectrum Disorder
12/25
12/25
Gammie, James S
PACES, NCT04045665 / 2021-005022-18: Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Recruiting
3
3200
Europe, Canada, US
Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
Icahn School of Medicine at Mount Sinai, National Heart, Lung, and Blood Institute (NHLBI), Vanderbilt University Medical Center
Atrial Fibrillation, Stroke, Bleeding
06/25
06/25
SCAD, NCT06310174: Study Examining the Effect of a Novel Cannulation Knife on User Satisfaction and Common Central Venous Catheter Insertion Complications

Recruiting
N/A
144
US
Johns Hopkins University
Central Venous Catheter Exit Site Infection
03/26
05/27
ICE-AFIB, NCT03732794: AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment

Active, not recruiting
N/A
150
US
AtriCure CryoICE & AtriClip LAA Exclusion
AtriCure, Inc.
Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation
06/24
06/26
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Recruiting
N/A
1056
Europe, Canada, US
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Medtronic Cardiovascular
Mitral Valve Regurgitation
10/26
09/36
EMPRO, NCT06027788: CTSN Embolic Protection Trial

Recruiting
N/A
842
Canada, US
CardioGard Embolic Protection Cannula, Standard Aortic Cannula
Icahn School of Medicine at Mount Sinai, National Heart, Lung, and Blood Institute (NHLBI)
Delirium, Ischemic Stroke, Acute Kidney Injury, Heart Valve Disease, Coronary Artery Disease
04/27
04/27
PRIMARY, NCT05051033: Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds

Recruiting
N/A
450
Europe, Canada, US
Mitral valve repair, Mitral valve surgery, Transcatheter edge-to-edge repair, TEER
Annetine Gelijns, National Heart, Lung, and Blood Institute (NHLBI)
Mitral Valve Regurgitation
11/28
11/30
Jindal, Gaurav
CREST-H, NCT03121209: Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics

Active, not recruiting
3
385
Canada, US
Revascularization, Intensive Medical Management (IMM) alone
Columbia University, National Institute of Neurological Disorders and Stroke (NINDS), Mayo Clinic, University of Alabama at Birmingham, University of Maryland, University of California, Los Angeles
Internal Carotid Artery Stenosis, Cognitive Impairment
01/27
07/27
Kuo, Irene
CHOICE-STAR, NCT06513156: Continuum of Care in Hospitalized Patients with Opioid Use Disorder and Infectious Complications from Drug Use

Recruiting
N/A
608
US
Integrated Infectious Diseases and Medication for Opioid Use Disorder Clinic (IC), NavSTAR-CHOICE (NS)
Elana Rosenthal, Emory University, George Washington University, West Virginia University, Weill Medical College of Cornell University, Friends Research Institute, Inc.
Opioid Use Disorder, Injection Related Infections
04/28
04/28
Reed, Robert
NCT06376994: Multi-Center Clean Air Randomized Controlled Trial in COPD

Recruiting
3
770
US
Air cleaner, Sham air cleaner
JHSPH Center for Clinical Trials, National Heart, Lung, and Blood Institute (NHLBI)
Chronic Obstructive Pulmonary Disease (COPD)
09/27
09/28
NCT05119556: Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease

Recruiting
N/A
768
US
Video Telehealth Pulmonary Rehabilitation
University of Alabama at Birmingham, National Heart, Lung, and Blood Institute (NHLBI)
Chronic Obstructive Pulmonary Disease
06/26
08/27
ALAMO, NCT05050955: AlloSure Lung Assessment and Metagenomics Outcomes Study

Recruiting
N/A
500
Canada, US
CareDx
Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
12/28
12/28
Doctor, Allan
PhITHy-Ho, NCT06129825: Pharmacologic Induction of Tolerance for Hypoxia & Hypothermia

Recruiting
N/A
50
US
Prospective
University of Maryland, Baltimore, United States Department of Defense
Hypothermia, Hypoxia, Mountain Sickness
12/25
07/26
Taylor, Bradley K
NCT02976337: Effect of High-dose Naloxone Following Third Molar Extraction

Completed
2
23
Europe
Naloxone, Naloxon "B. Braun", Normal Saline, Physiologic Saline
mads u werner, University of Kentucky
Healthy Subjects, Hyperalgesia, Inflammations, Endodontic, Pain, Acute, Sensitization, Central
11/23
12/23
TRIOMPHE, NCT04471909: NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness

Recruiting
N/A
110
US, RoW
NEXUS Aortic Stent Graft System
Endospan Ltd.
Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
11/24
10/29
RelayBranch, NCT03214601: Early Feasibility Study of the Thoracic Stent-Graft System

Active, not recruiting
N/A
30
US
penetrating atherosclerotic ulcer, aorta branch cardiovascular implant, Relay Branch System, system, endovascular graft, aortic aneurysm treatment
Bolton Medical
Thoracic Aorta Aneurysm, Aneurysm, Ruptured, Aortic Aneurysm
09/23
08/28
STAR-T, NCT04976530: Safe and Timely Antithrombotic Removal - Ticagrelor

Completed
N/A
140
Canada, US
DrugSorb-ATR system, Sorbent hemoperfusion system, Sham comparator
CytoSorbents, Inc
Hemorrhage, Surgical, Blood Loss, Surgical, Blood Loss, Postoperative, Hemorrhage Postoperative
08/23
08/23
SSB 11-02, NCT02777528: Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta (Zone 0/1)

Active, not recruiting
N/A
150
Japan, US
GORE® TAG® Thoracic Branch Endoprosthesis, Revascularization Procedure
W.L.Gore & Associates
Aortic Aneurysm, Thoracic, Aorta, Lesion
03/24
03/28
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation

Recruiting
N/A
958
Canada, US
Tendyne Mitral Valve System, MitraClip System
Abbott Medical Devices
Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease
05/24
06/28
NCT04482062: TRISCEND II Pivotal Trial

Active, not recruiting
N/A
1070
Europe, US
Edwards EVOQUE System, Transcatheter tricuspid valve replacement, Optimal Medical Therapy
Edwards Lifesciences
Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure
06/24
12/29
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Recruiting
N/A
1056
Europe, Canada, US
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Medtronic Cardiovascular
Mitral Valve Regurgitation
10/26
09/36
Nangia, Chaitali
BRIA-ABC, NCT06072612: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting
3
404
US
SV-BR-1-GM, Part of the Bria-IMT regimen, Cyclophosphamide, Interferon infiltration of the inoculation site, Retifanlimab, Treatment of Physician's Choice
BriaCell Therapeutics Corporation
Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer
06/25
12/25
QUILT-88, NCT04390399: Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Checkmark Data from QUILT 88 trial in combination anti–PD-L1 NK cell therapy in advanced pancreatic cancer at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT 88 trial in combination anti–PD-L1 NK cell therapy in advanced pancreatic cancer at ASCO 2022
Hourglass Jul 2021 - Sep 2021 : Anticipated enrollment of Cohort C in metastatic 3L pancreatic cancer
Active, not recruiting
2
328
US
N-803, Aldoxorubicin HCl, PD-L1 t-haNK, Nab-paclitaxel, Gemcitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, SBRT, Irinotecan liposome
ImmunityBio, Inc.
Pancreatic Cancer
10/25
10/25
NCT06710288: A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

Recruiting
2
20
US
Gemcitabine, gemcitabine hydrocholoride, Gemzar, N-803, M-CENK, Autologous Memory Cytokine Enriched Natural Killer
ImmunityBio, Inc.
Platinum-resistant Ovarian Cancer
05/27
05/27
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
BRI-ROL-001, NCT03328026: Combination Study of SV-BR-1-GM With Retifanlimab

Checkmark In combination with Bria-IMT for advanced breast cancer
Sep 2019 - Sep 2019: In combination with Bria-IMT for advanced breast cancer
Checkmark Anticipated efficiency data in combination with Bria-IMT
Dec 2018 - Dec 2018: Anticipated efficiency data in combination with Bria-IMT
Checkmark Safety data in combination with Bria-IMT
More
Enrolling by invitation
1/2
36
US
SV-BR-1-GM, Low dose cyclophosphamide, Cytoxan, Interferon Inoculation, retifanlimab, INCMGA00012
BriaCell Therapeutics Corporation, LumaBridge
Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic
11/25
11/28
Amelia-1, NCT05455619: Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Women With a PI3K Alteration and HR+/Her2- Breast Cancer

Recruiting
1/2
52
US
Evexomostat, SDX-7320
SynDevRx, Inc.
HR+/HER2-negative Breast Cancer, Metastatic Breast Cancer
03/26
09/26
NCT03743298: Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma

Recruiting
1b
20
US
AV-MEL-1
Aivita Biomedical, Inc.
Metastatic Melanoma
05/24
05/26
NCT04942054: A Study in Patients With Advanced Breast Cancer

Terminated
1
9
US, RoW
Part 1, Part 2, Part 3
Sun Pharma Advanced Research Company Limited
HER2-negative Breast Cancer, Advanced Breast Cancer, Hormone Receptor-positive Breast Cancer
02/23
02/23
DRAGON, NCT04291079: SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

Active, not recruiting
1
112
US, RoW
SRK-181, anti-PD-(L)1 antibody therapy
Scholar Rock, Inc.
Cancer
12/24
12/24
NCT04898543: QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
1
50
US
M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B), N-803 (Cohort 2 part B), Apheresis collection of MNCs (part A)
ImmunityBio, Inc.
Metastatic Solid Tumor
03/25
03/25
QUILT-3.100, NCT05976828: IBRX-042 in Participants with HPV-Associated Tumors

Recruiting
1
12
US
IBRX-042, IBRX-042 (hAd5-HPV E6.ETSD-IRES-E7.ETSD Vaccine)
ImmunityBio, Inc.
HPV-Related Carcinoma
09/25
08/33
NCT04595838: A Trial Assessing Chemo Mouthpiece Device With Best Supportive Care for Symptoms of Chemotherapy-Induced Oral Mucositis

Completed
N/A
176
US
Chemo Mouthpiece, Oral cryotherapy delivery device, Best Supportive Care only
Chemo Mouthpiece
Oral Mucositis
05/23
05/23
Chumsri, Saranya
NCI-2020-00332, NCT04249622: Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients with Stage I-III HER2 Positive Breast Cancer

Active, not recruiting
2
20
US
Best Practice, standard of care, standard therapy, Questionnaire Administration, Rifaximin, Xifaxan
Mayo Clinic, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC V8, Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage IB Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8
12/22
08/25
NCT05447910: Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer

Completed
2
21
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Letrozole, CGS 20267, Femara
Mayo Clinic
Breast Adenocarcinoma, Invasive Breast Carcinoma, Resectable Breast Carcinoma
09/23
09/23
ACCRU-BR-1701, NCT04197687: TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Recruiting
2
480
US
Multi-epitope HER2 Peptide Vaccine TPIV100, HER2/Neu Peptide Vaccine TPIV100, Peptide Vaccine TPIV100, TPIV 100, TPIV-100, TPIV100, Pertuzumab, 2C4, 2C4 Antibody, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, Placebo Administration, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
01/25
01/25
STOP-HER2, NCT05721248: Stopping Trastuzumab in HER2+ MBC

Recruiting
2
82
US
Cessation of anti-HER2 treatment
Dana-Farber Cancer Institute, National Cancer Institute (NCI), Gateway for Cancer Research, Susan G. Komen Breast Cancer Foundation, Translational Breast Cancer Research Consortium, Johns Hopkins University
Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer
02/26
02/36
NCT03106415: Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer

Completed
1/2
23
US
Binimetinib, ARRY-162, ARRY-438162, MEK162, Mektovi, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Mayo Clinic
Breast Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
05/22
05/22
ELU-FRα-1, NCT05001282: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Terminated
1/2
79
US
ELU001, FA-CDC
Elucida Oncology
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
06/24
06/24
BRI-ROL-001, NCT03328026: Combination Study of SV-BR-1-GM With Retifanlimab

Checkmark In combination with Bria-IMT for advanced breast cancer
Sep 2019 - Sep 2019: In combination with Bria-IMT for advanced breast cancer
Checkmark Anticipated efficiency data in combination with Bria-IMT
Dec 2018 - Dec 2018: Anticipated efficiency data in combination with Bria-IMT
Checkmark Safety data in combination with Bria-IMT
More
Enrolling by invitation
1/2
36
US
SV-BR-1-GM, Low dose cyclophosphamide, Cytoxan, Interferon Inoculation, retifanlimab, INCMGA00012
BriaCell Therapeutics Corporation, LumaBridge
Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic
11/25
11/28
NCI-2021-03139, NCT04857697: Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer

Completed
1
6
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Probiotic, Therapeutic Conventional Surgery
Mayo Clinic
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Adenocarcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
03/23
03/23
NCT04144023: A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

Recruiting
1
43
US
Granulocyte-Macrophage Colony-Stimulating Factor, Colony Stimulating Factor 2, Colony Stimulating Factor, Granulocyte-Macrophage, Colony-Stimulating Factor, Colony-Stimulating Factor 2, CSF, CSF2, GM CSF, GM-CSF, GMCSF, Granulocyte Macrophage Colony Stimulating Factor, Granulocyte Macrophage Colony-Stimulating Factor, Granulocyte-Macrophage Colony Stimulating Factor, Multi-epitope HER2 Peptide Vaccine H2NVAC, H2NVAC, HER2 Peptide Vaccine H2NVAC, HER2 Specific Helper T-cell Epitope Vaccine H2NVAC, Therapeutic Conventional Surgery, Echocardiography, EC, ECHO, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Biopsy, BIOPSY_TYPE
Mayo Clinic, National Cancer Institute (NCI)
Breast Ductal Carcinoma In Situ
12/25
12/25
NCT04865133: Efficacy and Safety of COVID-19 Vaccine in Cancer Patients

Completed
N/A
89
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Electronic Health Record Review
Mayo Clinic
COVID-19 Infection, Malignant Solid Neoplasm
09/22
09/22
NCT06508034: Probiotics for the Prevention of Immunotherapy Induced Colitis in Patients Receiving Immunotherapy

Recruiting
N/A
30
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Live Freeze-Dried Lactic Acid Bacteria Probiotic, VSL#3, VSL3, Questionnaire Administration
Mayo Clinic
Malignant Solid Neoplasm
08/27
08/27
NCT04517838: Immune Response to Anti-HER2 Therapies in Patients with HER2-Positive Stage I-IV Breast Cancer

Recruiting
N/A
750
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection
Mayo Clinic
Breast Adenocarcinoma, HER2-Positive Breast Carcinoma
07/27
07/28
Bennett, Melanie E
NCT02455349: Improving Negative Symptoms and Community Engagement in Veterans With Schizophrenia

Recruiting
N/A
108
US
Engaging in Community Roles &Experiences, Health & Wellness
VA Maryland Health Care System
Schizophrenia
05/19
05/19
NCT04367506: Pilot Testing a Digital Intervention to Improve Smoking Cessation in Persons With Serious Mental Illness

Active, not recruiting
N/A
59
US
BecomeAnEX, Usual Care
University of Maryland, Baltimore, Sheppard Pratt Health System, Truth Initiative
Tobacco Cessation
07/24
12/24
NCT04624074: Pilot Testing the Check Up

Recruiting
N/A
40
US
Teen Marijuana Check Up
University of Maryland, Baltimore
Cannabis Use Disorder
06/25
06/25
HEAL Together, NCT05299515: Peer Activate: Trial of Peer-Delivered Behavioral Activation for Methadone Adherence

Recruiting
N/A
200
US
Peer-Delivered Behavioral Activation ("Peer Activate")
University of Maryland, College Park, University of Maryland, Baltimore, Henry Ford Health System
Substance-Related Disorders, Opioid Medication Assisted Treatment, Opioid Use Disorder, Opioid Use, Opioid Addiction, Treatment Adherence, Retention in Care
06/25
06/25
NCT06583239: Hub-Based Engagement Navigator Service to Reduce CSC Disengagement

Not yet recruiting
N/A
555
US
Engagement Navigator Service (ENS)
University of Maryland, Baltimore
Disengagement
07/29
07/29
CP-SMI, NCT06758414: CBT-CP for Veterans With SMI

Not yet recruiting
N/A
190
US
Cognitive Behavioral Therapy for Chronic Pain (CBT-CP), Health & Wellness (H&W)
VA Office of Research and Development
Chronic Pain, Schizophrenia, Psychotic Disorders, Bipolar Disorder, Affective Disorders, Psychotic
09/29
09/29
Hochberg, Marc C
NCT05406726: Mechanisms of Palmitoylethanolamide (PEA) to Alter Pain Sensitivity in Knee Osteoarthritis

Completed
N/A
13
US
palmitoylethanolamide, PEA, Placebo, Maltodextrin
University of Maryland, Baltimore
Osteoarthritis, Knee
01/24
01/24
Deeley, Maura
SPRAY-CB, NCT03893370: RejuvenAir® System Trial for COPD With Chronic Bronchitis

Active, not recruiting
N/A
210
Europe, US
RejuvenAir System, Sham Control Procedure
CSA Medical, Inc.
Chronic Bronchitis
05/25
09/26
Almardawi, Ranyah
NCT04579692: MR Guided Focused Ultrasound (FUS) for the Treatment of Trigeminal Neuralgia

Recruiting
N/A
10
US
ExAblate Transcranial treatment, The ExAblate® MR guided focused ultrasound system
University of Maryland, Baltimore, Focused Ultrasound Foundation, InSightec
Trigeminal Neuralgia
06/25
06/25
Coordinator, Research
CAMPLIFE, NCT06562296: Study Evaluating Several CAMPs in Nonhealing Diabetic Foot and Venous Leg Ulcers

Recruiting
4
292
US
Amnion-Intermediate-Chorion, AIC, Amnion-Chorion-Amnion, ACA, Standard of Care, SOC
Cellution Biologics, SerenaGroup, Inc., LifeCell
Diabetic Foot Ulcer, Venous Leg Ulcer
12/26
07/27
TOPAZ, NCT03924414: Trial of Parkinson's And Zoledronic Acid

Recruiting
4
2650
US
Zoledronic Acid 5Mg/Bag 100Ml Inj, Reclast, Placebo
California Pacific Medical Center Research Institute, National Institute on Aging (NIA), University of California, San Francisco, Duke University, University of Pittsburgh, Parkinson's Foundation
Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism, Atypical Parkinsonism, Progressive Supranuclear Palsy, Multiple System Atrophy, Vascular Parkinsonism, Dementia With Lewy Bodies
10/25
10/25
NCT05078827: Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

Completed
3
458
US
Test Product (A): Fluorouracil Cream, 5% topical cream, Experimental, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., Active Comparator, Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India, Placebo Comparator
Encube Ethicals Pvt. Ltd., CBCC Global Research
Actinic Keratoses
11/22
12/22
ReMMi-D, NCT05853900: Study of Two Digital Therapeutics for the Prevention of Episodic Migraine

Completed
3
558
US
ReMMi-D Digital Therapeutic
Click Therapeutics, Inc.
Migraine, Episodic Migraine, Headache, Headache, Migraine
05/24
05/24
OPERA-T, NCT05238116 / 2021-004554-32: Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis ( Study)

Recruiting
3
123
Europe, Canada, US, RoW
PC945, Placebo
Pulmocide Ltd
Refractory IPA
03/26
04/26
NCT06004388: Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)

Completed
3
110
US
Click Digital Therapeutic
Click Therapeutics, Inc.
Migraine, Episodic Migraine, Headache, Headache, Migraine
05/24
06/24
SKOAP, NCT04504812: A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain

Active, not recruiting
3
1800
US
Duloxetine, Cymbalta, Intra-Articular Injection, Nerve Procedure with long acting blocks, Nerve Procedure with nerve ablation, Pain Coping Skills Training, Best Practices
Johns Hopkins University, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Knee Osteoarthritis
03/25
03/25
CONVOKE, NCT05838625: Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia

Recruiting
3
432
US
Digital Therapeutic
Click Therapeutics, Inc., Boehringer Ingelheim
Schizophrenia
06/25
07/25
NCT06067984: An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia

Active, not recruiting
3
75
US
Study App
Click Therapeutics, Inc., Boehringer Ingelheim
Schizophrenia, Negative Symptoms in Schizophrenia
04/25
05/25
HEALEY ALS, NCT04297683: Platform Trial - Master Protocol

Active, not recruiting
2/3
1500
US
ABBV-CLS-7262, DNL343
Merit E. Cudkowicz, MD, Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
07/25
04/26
NCT06365437: A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

Completed
2
33
Europe
TCD601, Siplizumab, Tacrolimus (TAC), Corticosteroids (CS), Mycophenolate Mofetil (MMF), ATG
ITB-Med LLC
Kidney Transplantation
12/24
12/24
 

Download Options